With reference to the report published, the global Immunohistochemistry Market size was priced at USD 1.8 billion in 2019. It is expected to observe a 7.8% CAGR throughout the period of the forecast.
The reasons, like the initiation of technically superior Immunohistochemistry resolution, rising actions of medicine invention and improvement, plus the increasing occurrence of persistent sickness are estimated to considerably energize the expansion of the market, for the duration of the forecast.
The same as the vital function of polyclonal and monoclonal antibodies, Immunohistochemistry assist in understanding the tissue division of an antigen. It is utilized in the discovery of tumor cell creation, tumor suppressor genes, enzymes as well as antigens. Immunohistochemistry has achieved fame in the area of clinical diagnostics, since it is utilized in the identification of persistent sicknesses, like cardiovascular illnesses, cancer, autoimmune disorders, and infectious diseases. Therefore, the increasing occurrence of persistent sicknesses is expected to boost the demand for Immunohistochemistry resolutions, contributing to the enlargement of the market.
Growing approvals for the product, along with the induction of technically superior Immunohistochemistry resolutions for the identification of the disease, is additionally powering the expansion of the Immunohistochemistry (IHC) market. Such as, the U.S. centered Biocare Medical, LLC presented p16 INK4a, a new mouse monoclonal antibody, planned for the qualitative discovery of the p16 INK4a protein, by means of Immunohistochemistry, in September 2019. Additionally, F. Hoffmann-La Roche AG, the important company operating in the market for Immunohistochemistry presented its innovative automated Ventana pan-tropomyosin receptor kinase (TRK) (EPR17341) Assay, in 2018. This recently introduced Immunohistochemistry examination is aimed at the discovery of TRK proteins in the patients painting due to cancer.
The need for specificity, linked with the Immunohistochemistry method, and its elevated prices of the setup, is expected to hinder the enlargement of the immunohistochemistry market. Before time and precise finding of the cancerous development is extremely vital in the administration of the sickness. On the other hand, there is a shortage of specificity with the Immunohistochemistry method, to make a diagnosis of several of the persistent sickness that possibly will impede its implementation. The greater setup charges of immunohistochemistry apparatus create a vast burden on diagnostic laboratories and hospitals in emergent nations, thus restraining the expansion of the market.
The majority apprehension for all the governments of the Covid-19 influenced nation is the severe requirement to monitor and an examination of outsized records of the patients for the probable Sars-Cov-2 disease. Accordingly, the majority of them are in front of major scarcity in the source for diagnostic kits, to check for the virus. Diagnostics virology units are below huge pressure, to offer dependable testing kits, and there is a gush in demand for the point-of-care testing capability, via labs, from a number of nation-states.
The market is classified into diagnostics and drug testing, on the basis of application. In 2019, the diagnostics section retained the principal share of the market and is estimated to observe a productive CAGR, for the period of the forecast. The diagnostics section is additionally segregated into nephrological, cardiovascular, infectious, autoimmune diseases, diabetes, and cancer. The global augmentation in the occurrence of these persistent sicknesses is increasing the demand for precise and fast diagnosis, thus powering the enlargement of the diagnostics sector.
The immunohistochemistry market is classified into kits, antibodies, reagents, and equipment, on the source of the product. Antibodies retained the major share of the market in 2019, due to their constant usage in immunohistochemistry actions for the medical test and the diagnosis of illness. Antibody-associated products, for example, antibody-drug conjugates, Fc-fusion proteins, and antibody fragments along with therapeutic monoclonal antibodies have turn into the most important product category, in the market. Antibodies are furthermore classified into primary and secondary antibodies. In 2019, the primary antibodies section ruled the market, since these are mainly utilized in the diagnosis of persistent diseases and are expected to preserve their share in the market for the period of the forecast.
On the source of end-use, the immunohistochemistry (IHC) market is classified into diagnostic laboratories, research institutes, hospitals, and others. As a result of the growth in the demand for sickness diagnosis, caused by the increase in the frequency of chronic ailments, diagnostic laboratories and hospitals retained the principal share of the market, in 2019. In addition, scientific progression such as digital pathology and automatic preparation of the sample has added significant importance. Besides, the augmentation in the figure of clinical research laboratories has, furthermore, improved the demand for diagnostics, therefore impelling the expansion of the section.
Due to fast financial growth in the nations such as Singapore, India, China, and South Korea, Asia Pacific is projected to display a maximum enlargement. Also, the speedily growing old populace, in addition to the high-pitched occurrence of persistent illnesses, is moreover expected to be important factors, compelling the market for Immunohistochemistry. Derived from WHO approximation, yearly events of CVDs are expected to go up by 50% in China, between 2010 and 2030.
In terms of revenue, North America retained the foremost place, in 2019 and is expected to sustain its supremacy in the market, during the period of the forecast. North America owns a deeply rooted infrastructure of healthcare. This has initiated a boost in the acceptance of Immunohistochemistry apparatuses, in diagnostic centers along with the laboratories. The encouraging compensation structure, in this area, is furthermore increasing the infiltration of automatic devices in the market. Additionally, the occurrence of cancer is rising within this state. This is furthermore powering the demand for Immunohistochemistry procedures, thus leading to the productive development of the market.
The key companies concentrate on implementing the policies of natural development like the up-gradation, as well as the development of the product, so as to build up its position and to take the main share of the market. Such as, Germany-centered company Leica Biosystems, which is a completely owned supplementary of Danaher Corporation, introduced an advanced category of its BOND-III ISH stainer and IHC, in March 2018. This recently inaugurated new version of the BOND-III possesses improved and the user-friendliness of together the software as well as the hardware of the apparatus. Likewise, PerkinElmer declared the release of Vectra Polaris, Automated Quantitative Pathology Imaging System, in January 2017. This mechanism is intended to offer the researchers, a superior awareness of cancer immunotherapy methodology.
• Abcam plc.
• Bio SB
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Agilent Technologies, Inc.
• Cell Signaling Technology, Inc.
• PerkinElmer, Inc.
• Merck KGaA
• Thermo Fisher Scientific, Inc.
Report Attribute |
Details |
The market size value in 2020 |
USD 1.8 billion |
The revenue forecast in 2027 |
USD 3.2 billion |
Growth Rate |
CAGR of 7.8% from 2020 to 2027 |
The base year for estimation |
2019 |
Historical data |
2016 - 2018 |
Forecast period |
2020 - 2027 |
Quantitative units |
Revenue in USD Million & CAGR from 2020 to 2027 |
Report coverage |
Revenue forecast; company share; competitive landscape; growth factors and trends |
Segments covered |
Product, application, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; U.K.; Germany; Spain; France; Italy; Russia; Japan; India; China; South Korea; Singapore; Australia; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE |
Key companies profiled |
Abcam plc; Agilent Technologies; Bio SB; Bio-Rad Laboratories, Inc.; Cell Signaling Technology, Inc.; Danaher Corporation; F. Hoffmann-La Roche AG; Merck KGaA; PerkinElmer, Inc.; Thermo Fisher Scientific, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country; regional & segment scope. |
Pricing and purchase options |
Avail of customized purchase options to meet your exact research needs. |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Million Insights has segmented the global immunohistochemistry market report on the basis of product, application, end-use, and region:
• Product Outlook (Revenue, USD Million, 2016 - 2027)
• Antibodies
• Primary Antibodies
• Secondary Antibodies
• Equipment
• Slide Staining Systems
• Tissue Microarrays
• Tissue Processing Systems
• Slide Scanners
• Others
• Reagents
• Histological Stains
• Blocking sera and Reagents
• Chromogenic Substrates
• Fixation Reagents
• Stabilizers
• Organic Solvents
• Proteolytic Enzymes
• Diluents
• Kits
• Application Outlook (Revenue, USD Million, 2016 - 2027)
• Diagnostics
• Cancer
• Infectious Diseases
• Cardiovascular Diseases
• Autoimmune Diseases
• Diabetes Mellitus
• Nephrological Diseases
• Drug Testing
• End-use Outlook (Revenue, USD Million, 2016 - 2027)
• Hospitals & Diagnostic Laboratories
• Research Institutes
• Others
• Regional Outlook (Revenue, USD Million, 2016- 2027)
• North America
• U.S.
• Canada
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• The Asia Pacific
• Japan
• China
• India
• South Korea
• Singapore
• Australia
• Latin America
• Brazil
• Mexico
• Argentina
• MEA
• South Africa
• Saudi Arabia
• UAE
Research Support Specialist, USA